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New drugs for an ancient parasite
Alex Loukas & Jeffrey M Bethony
Only one drug is widely used to treat schistosomiasis, a chronic, neglected tropical disease caused by parasitic blood 
flukes. Fears of potential drug resistance have accelerated the search for new classes of antischistosome drugs. A 
promising candidate has now emerged (pages 407–412).
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Schistosomiasis, caused by blood flukes of 
the genus Schistosoma (Fig. 1), has afflicted 
humans for thousands of years and is argu-
ably the most important human helminth 
infection. Schistosomes infect more than 
200 million people in 76 countries and are 
responsible for up to 20,000 deaths per year. 
Eggs of the parasite become trapped in tis-
sues such as the bowel or bladder, leading to 
chronic immunopathology.
Recent assessments of the public health 
impact of schistosomiasis include not only 
gross organ pathology, but also the anemia, 
pain, diarrhea, exercise intolerance and 
undernutrition that results from chronic 
infection, raising the estimate of disabil-
ity previously assigned to the disease by 
the World Health Organization (WHO)1,2. 
Schistosomiasis can be treated with anthel-
mintic agents, but the current reliance on 
a single drug, praziquantel, has prompted 
fears of the emergence of drug-resistant 
parasites.
In this issue of Nature Medicine, Sayed et 
al.3 provide hope for the development of 
new antischistosome drugs. By targeting the 
antioxidant pathway, the authors identified a 
family of compounds that interrupt the abil-
ity of the parasite to detoxify reactive oxygen 
species and kill schistosomes in vitro and in 
animal models of infection. If their results 
hold true in human clinical trials, this class 
of compound has the potential to become a 
powerful new tool for the control of schis-
tosomiasis.
The mainstay of current schistosomiasis 
control is the anthelmintic drug praziquantel 
(PZQ), a quinoline compound developed in 
the 1970s by Bayer as an anthelmintic drug 
for veterinary parasites. PZQ causes calcium 
ion fluxes, which results in contraction of 
parasite muscle followed by paralysis and 
death of the worm. The WHO places PZQ 
on its ‘Essential Medicines’ register, which 
catalogs “minimum medicine needs for 
basic health care systems.”4. The affordabil-
ity, efficacy and safety of PZQ prompted the 
formation of the Schistosomiasis Control 
Initiative, an organization funded by the 
Bill and Melinda Gates Foundation that 
currently facilitates mass administration of 
PZQ in six African countries. Some people 
in the Schistosomiasis Control Initiative 
believe that mass administration of PZQ 
will consign schistosomiasis to history by 
20155, but concerns about the sustainabil-
ity of these efforts remain. This is because 
of lower-than-expected efficacies of single-
dose PZQ, high rates of reinfection after 
treatment and the potential emergence of 
anthelminthic drug resistance. Indeed, PZQ 
resistance has already been documented in 
the laboratory6. Given such weaknesses in 
this single-drug regimen, there is a pressing 
need for new control tools.
Alternative drugs are available to treat 
schistosomiasis, but they have drawbacks. 
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Figure 1  An adult male Schistosoma mansoni.
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Artemether (artemisinin) is derived from a 
Chinese plant and can treat a range of para-
sitic infections. Although artemether is safe 
and effective against schistosomes, a major 
obstacle to its use is that it is considered the 
last line of defense for treating multidrug-
resistant malaria, which is often coendemic 
with schistosomiasis, especially in Africa, and 
thus using it to treat schistomsomiasis may 
result in artemether-resistant malaria.
The present discovery of the new com-
pounds is the result of the first assay officially 
accepted for screening by the US National 
Institutes of Health Molecular Libraries 
Initiative, a partnership developed to enable 
academic researchers to apply a biotech 
company–type approach to drug discovery 
and preclinical testing. The new compounds 
target an enzyme involved in detoxifying 
antioxidants in the parasites.
Schistosomes are unique in the way they 
deal with antioxidants, both their own and 
those generated by the host’s immune system. 
Vertebrates detoxify reactive oxygen species 
using two distinct enzymes—glutathione 
reductase and thioredoxin reductase. Sayed 
et al.3 built upon their previous biochemical 
and bioinformatic data, which supported the 
notion that S. mansoni uses just one unique, 
multifunctional detoxifying enzyme. This 
enzyme, thioredoxin-glutathione reductase 
(TGR), has both glutathione reductase and 
thioredoxin reductase activities8. Using a 
fully automated, high-throughput format, 
the authors screened 71,028 compounds for 
TGR inhibitory activity9. Several compounds 
that were active in the low micromolar to 
nanomolar ranges were identified, including 
the oxadiazole 2-oxides9.
Sayed et al.3 showed that the oxadiazole 
2-oxide 4-phenyl-1,2,5-oxadiazole-3-carbo-
nitrile-2-oxide (which they refer to as com-
pound 9) irreversibly bound to TGR and 
inhibited its enzymatic activity, probably 
via modification of cysteine or selenocys-
teine residues in the protein. Most impor-
tantly, these new oxadiazoles (particularly 
compound 9) held their own against PZQ 
and artemether: in vitro they could kill all 
intramammalian developmental stages of 
schistosomes (skin and lung larvae as well 
as juvenile and adult worms). In contrast, 
PZQ and artemether target mainly the adult 
and larval stages, respectively.
Compound 9 was tested for efficacy in a 
mouse model of S. mansoni infection, and 
88–99% reductions in worm burdens were 
obtained irrespective of the timing of the 
treatment. Moreover, the activity of com-
pound 9 surpassed all criteria set forth 
by the WHO for potential new drugs for 
schistosomiasis. Compound 9 was also 
equally efficacious against two other com-
mon human schistosomes, Schistosoma 
haematobium and Schistosoma japonicum. 
S. haematobium is the cause of urogenital 
schistosomiasis (which can result in bladder 
cancer), and this parasite is responsible for 
the majority of schistosome-related mor-
bidity in Africa10. Although less prevalent 
than the African species, S. japonicum is an 
aggressive parasite in terms of pathology; 
however, the burden of disease associated 
with it throughout Asia is not well estab-
lished2.
A collaboration between academic labo-
ratories developed and funded this research, 
so it seems that similar partnerships could 
ensure the progression of this drug through 
the development pipeline and into clinical 
trials. Public-private partnerships are prov-
ing to be a successful model for the devel-
opment of new drugs for neglected tropical 
diseases11. Such organizations are crucial, 
given the lack of interest by large pharma-
ceutical companies in developing medicines 
without a large commercial market.
It is, however, important to emphasize 
that drugs are only one link in the chain of 
sustainable schistosomiasis control (Fig. 2). 
Emphasis should be placed on integrated 
mechanisms that prevent, as well as cure, 
schistosomiasis to achieve eradication. 
Vaccines are an essential component in 
such a sustainable control program and offer 
the ability to prevent infection and reinfec-
tion, especially when coadministered with 
anthelmintic drugs. Indeed, recent advances 
in genomics and proteomics have resulted in 
the discovery of new antigens that are show-
ing promise as recombinant vaccines and are 
in various stages of clinical development12. 
Moreover, a truly integrated approach to 
control would include infrastructure and 
education components. Such an integrated 
approach would require longer-term invest-
ments, but the consequences would reach far 
beyond the control of just schistosomiasis.
Despite a dearth of funding for basic 
schistosomiasis research from major phil-
anthropic organizations, it is reassuring to 
see that groundbreaking advances are still 
being made to control this illness—one of 
the most crippling and unrelenting of the 
tropical diseases.
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Figure 2  An integrated approach is needed to eliminate schistosomiasis.  Linking vaccination with 
chemotherapy, together with a program of clean water and health education, would offer the most 
effective long-term approach to reducing infection and morbidity from schistosomiasis.  This requires 
short-term goals (purple arrows) and long-term, often more ambitious, goals (green arrows).
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Dropping acid to help cystic fibrosis
Gerald B Pier
Vesicular accumulation of the membrane component ceramide may underlie key aspects of lung pathology in cystic 
fibrosis (pages 382–391).
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Breathing is basic—as anyone who has 
ever struggled for adequate oxygen, which 
is virtually everyone, can readily attest. 
Compromises to the lung that affect oxygen-
ation of tissues can seriously threaten health. 
The lungs, like other mucosal surfaces, are 
major ports of entry for microbes, but mam-
mals must keep their lungs sterile, unlike the 
gastrointestinal or vaginal mucosa. They do 
so by relying on an effective innate and adap-
tive immune system to rapidly clear patho-
gens while minimizing consequences from 
inflammatory responses.
The hereditary disease cystic fibro-
sis occurs as a consequence of having two 
defective alleles of the gene encoding an 
epithelial chloride channel, the cystic fibro-
sis transmembrane conductance regulator 
(CFTR). Both chronic infection and chronic 
inflammation collude to destroy lung tis-
sues, reduce the ability of affected people to 
breathe adequately and bring about an early 
death, often before 40 years of age, primar-
ily owing to respiratory failure. How muta-
tions in CFTR actually cause lung disease on 
a molecular and cellular level is still an area 
of intense investigation, particularly with 
regard to whether an absence of functional 
CFTR alone causes inflammation in the lung 
and to why one single pathogen, the Gram-
negative bacterium Pseudomonas aeruginosa, 
is such an overwhelming cause of destructive 
infection and inflammation.
Findings in this issue of Nature Medicine 
address a key aspect of these questions. 
Teichgräber et al.1 find that the membrane 
component ceramide accumulates abnor-
mally in respiratory epithelial cells of trans-
genic cystic fibrosis mice and is also present 
in large amounts in nasal epithelial cells and 
lung tissues from humans with cystic fibro-
sis. Ceramide seems to induce endogenous 
inflammation while also enhancing the sus-
ceptibility of older cystic fibrosis mice to 
lung infection with P. aeruginosa. Ceramide 
accumulation contributes to the pathol-
ogy of the cystic fibrosis lung by promoting 
inflammatory cytokine production, cellular 
apoptosis and DNA accumulation, which 
serve as a nidus for initiating P. aeruginosa 
infection.
The authors sought to address an out-
standing question in cystic fibrosis research, 
which is whether the lack of functional CFTR 
induces an inflammatory state in the lung, 
even in the absence of infection1. Teichgräber 
et al.1 focused on sphingolipids, as they are 
known regulate the production of molecules 
that cause lung inflammation and affect cell 
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Figure 1  Enhancing inflammation and infection in the cystic fibrosis–affected airway. Synthesis of 
ceramide from sphingomyelin by acid sphingomyelinase (ASM) and degradation by acid ceramidase 
(AC) is optimal at an acidic pH, such as that of normal intracellular vesicles (pH 4.5). Lack of 
functional CFTR increases vesicle pH to 5.9, partially inhibiting ASM and highly inhibiting AC, 
resulting in ceramide accumulation in the vesicle and age-dependent pulmonary inflammation. 
Other properties of the cystic fibrosis–affected lung, including lack of the CFTR receptor needed 
for clearing Pseudomonas aeruginosa, enhanced mucin secretion, a dehydrated airway surface 
liquid, viscous mucus and DNA deposits released from ceramide-engorged apoptotic cells, also 
contribute to P. aeruginosa airway colonization. Eventually, this microbe establishes a chronic 
infection wherein bacterial cells reside in low-oxygen mucus plugs and become highly resistant to 
clearance or killing by host defenses.
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